Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

60.0%

9 terminated/withdrawn out of 15 trials

Success Rate

35.7%

-50.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

140%

7 of 5 completed trials have results

Key Signals

1 recruiting7 with results5 withdrawn

Enrollment Performance

Analytics

Phase 1
13(86.7%)
Phase 2
2(13.3%)
15Total
Phase 1(13)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials
NCT04776239Phase 1Completed

Allogeneic Mesenchymal Human Stem Cell Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects With Symptomatic Ischemic Heart Disease. (ACESO-IHD)

Role: lead

NCT04476901Phase 2Recruiting

Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

Role: lead

NCT02677350Phase 1Withdrawn

AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iNjEctions (GALENE)

Role: lead

NCT03406884Phase 1Completed

The CHILD Trial: Hypoplastic Left Heart Syndrome Study.

Role: lead

NCT03059355Phase 1Terminated

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.

Role: lead

NCT04490486Phase 1Withdrawn

Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19

Role: lead

NCT02886884Phase 1Completed

Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

Role: lead

NCT02013700Phase 1Terminated

Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)

Role: lead

NCT02503280Phase 1Withdrawn

The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.

Role: lead

NCT03487731Phase 1Withdrawn

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

Role: lead

NCT03058068Phase 1Withdrawn

Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis

Role: lead

NCT02013674Phase 2Completed

The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)

Role: lead

NCT00587990Phase 1Terminated

Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)

Role: lead

NCT02675556Phase 1Terminated

Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression

Role: lead

NCT01392625Phase 1Completed

PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)

Role: lead

All 15 trials loaded